Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib withdrawal study in pediatric systemic juvenile idiopathic arthritis
2017-004495-60Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in systemic juvenile idiopathic arthritis (SJIA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to disease flare. Started Jul 2019; status: active.
02
Drugs
baricitinib
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on 2017-004495-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004495-60.